Last Updated on February 27, 2025 by The Health Master
Inspection
The Rajasthan Medical Services Corporation Limited (RMSCL) recently visited pharmaceutical companies in Baddi, Himachal Pradesh for a surprise inspection in connection with the the safety and efficacy of medications provided under the Chief Minister’s Free Medicine Scheme
This proactive action was undertaken after the various media reports that raised concerns about the manufacturing and supplying of counterfeit drugs and irregularities within the pharmaceutical industry in the Baddi region.
Ensuring Quality and Safety
A team constituted with 4 members from the RMSCL, Rajasthan examined various aspects of the manufacturing and testing processes during their visit.
This includes:
The team checked the process of manufacturing and quality of drugs to ensure the best practices by these firms with respect to the rules and regulations of the drug department.
Storage facilities and conditions were also checked by the team to ensure the correct temperature and humidity as per the storage conditions of these drugs.
Assessment of the entire supply chain has also been done by the team to identify and ensure the quality of drugs.
Verification of compliance has also been done with all relevant regulatory standards and guidelines set by the Drug Control Department.
The team has also verified the manufacturing licenses, equipment calibration records, and testing facilities to ensure they meet the required standards of the drug control department.
Findings and Observations
While the surprise inspection revealed that the majority of the manufacturing units in Baddi met the required standard asertained by the department and were found to be operated with valid licenses.
The team also observed several units operating at international standards, producing and exporting large quantities of medicines worldwide.
Why was this inspection conducted y Rajasthan?
The team checked the process of manufacturing and quality of drugs to ensure the best practices by these firms with respect to the rules and regulations of the drug department.
What aspects of the manufacturing process were inspected?
The team checked and verified the manufacturing processes, storage conditions, supply chain management, regulatory compliance, and more.
Disclaimer: This article contains information obtained from the source mentioned below. Our team made changes in the format to rewrite and present the news or article in a unique format.
Key Notes on Revised Schedule M: Compilation
Important short notes for Industry and Regulators
CDSCO Guidelines on Drug Recall
Quality Assurance Vs Quality Control in the Pharma Industry
Major FDA audit findings about Equipment and Instruments
Understanding GMP, cGMP, and WHO-GMP
Quality Assurance in the Pharmaceutical Industry
Duties and responsibilities of QA person in Pharma Industry
Difference: Disintegration and Dissolution test in pharma industry
Understanding DQ, IQ, PQ, and OQ in the Pharma Industry
USFDA inspection at Zydus API plant with zero observations
Opportunity to Supply APIs to Venezuela: Pharmexcil
Digital program for Pharmacists launched
NPPA revised ceiling price of 2 formulations: February 2025
Extension of the deadline for Revised Schedule M: Final notification
NPPA fixed retail price of 42 formulations: February 2025
Drug prices display is mandatory for all pharmacies: NPPA
New export norms for Erythromycin Stearate Tablets: DGFT
